UpToDate
©2018 UpToDate
Empiric intravenous antibiotic therapy for animal bites
Adults Children
Options for empiric gram-negative and anaerobic coverage include:
Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following:
Ampicillin-sulbactam 3 g IV every six hours 50 mg/kg per dose (based on ampicillin component) every six hours*
Piperacillin-tazobactam 3.375 g IV every six hours 100 mg/kg per dose (based on piperacillin component) every eight hours*

A third-generation cephalosporin such as ceftriaxone 1 to 2 g IV every 24 hours

PLUS

Metronidazole 500 mg IV every eight hours

A third-generation cephalosporin such as ceftriaxone 100 mg/kg IV daily, given in one to two divided doses*

PLUS

Metronidazole 10 mg/kg IV per dose every eight hours*
Alternative empiric regimens include:

A fluoroquinolone (eg, ciprofloxacin 400 mg IV every 12 hours, levofloxacin 500 mg IV daily, or moxifloxacin 400 mg IV daily)

PLUS

Metronidazole 500 mg IV every eight hours

Use fluoroquinolones with caution in children <18 years of age; if unable to tolerate other choices:

A fluoroquinolone (ciprofloxacin 20 mg/kg IV per dose twice daily or levofloxacin 10 mg/kg IV per dose twice daily if <5 years old or once daily if ≥5 years)

PLUS

Metronidazole 10 mg/kg IV per dose every eight hours

Monotherapy with a carbapenem, such as one of the following:
Imipenem-cilastatin 500 mg every six hours 25 mg/kg per dose every six hours (maximum 500 mg per dose)
Meropenem 1 g every eight hours 20 mg/kg per dose every eight hours (maximum 1 g per dose)
Ertapenem 1 g daily

Children ≤12 years old: 15 mg/kg per dose every 12 hours (maximum 500 mg per dose)

Children >12 years old: Refer to adult dosing

The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency. Additional coverage for certain gram-positive pathogens may also be warranted, eg, if the patient has risk factors for colonization with community-acquired methicillin-resistant Staphylococcus aureus (MRSA). Refer to topic reviews of soft tissue infections due to dog and cat bites and MRSA treatment for recommendations.
IV: intravenously.
* Maximum pediatric dose: See adult dose.
¶ Carbapenems should not be routinely used in patients with a history of hypersensitivity to beta-lactams; skin testing and graded challenge may be useful for assessment of immediate-type hypersensitivity reactions. For recommendations, refer to UpToDate review of carbapenems use in penicillin-allergic patients.
References:

  1. American Academy of Pediatrics (AAP). Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed., Kimberlin DW, Brady MT, Jackson MA, Long SA, (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015.
  2. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147.
Graphic 63280 Version 8.0